Natural product-based therapy for Pulmonary Hypertension (PAH): Agaricus blazei Murill inhibits pulmonary hypertension via induction of PDLIM5, 7/February/2015, 07.50 am

Natural product-based therapy for Pulmonary Hypertension (PAH): Agaricus blazei Murill inhibits pulmonary hypertension via induction of PDLIM5, 7/February/2015, 07.50 am

Natural product-based therapy for Pulmonary Hypertension (PAH): Agaricus blazei Murill inhibits pulmonary hypertension via induction of PDLIM5, 7/February/2015, 07.50 am 150 150

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Significance: This study suggests, for the first time, that Agaricus blazei Murill, by suppressing the expression of its target gene, it may increase the expression of PDLIM5. Thereby, it may inhibit pulmonary hypertension. Together, pharmacological formulations encompassing “Agaricus blazei Murill or small molecule compounds isolated from Agaricus blazei Murill may be used to treat pulmonary arterial hypertension (PAH).

Amount: $ 500*

Undisclosed information: How Agaricus blazei Murill  increases the expression of PDLIM5

To citeBoominathan, Natural product-based therapy for Pulmonary Hypertension (PAH): Agaricus blazei Murill inhibits pulmonary hypertension via induction of PDLIM5, 7/February/2015,  07.50 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org